Clinical Oncology

  • Quizartinib tested in patients with high-risk AML June 21, 2018
    Quizartinib tested in patients with high-risk AMLQuizartinib tested in patients with high-risk AML, Published online: 22 June 2018; doi:10.1038/s41571-018-0061-8Quizartinib tested in patients with high-risk AML
    Peter Sidaway
  • Rituximab and ibrutinib synergize in Waldenström macroglobulinaemia June 20, 2018
    Rituximab and ibrutinib synergize in Waldenström macroglobulinaemiaRituximab and ibrutinib synergize in Waldenström macroglobulinaemia, Published online: 21 June 2018; doi:10.1038/s41571-018-0053-8Rituximab and ibrutinib synergize in Waldenström macroglobulinaemia
    David Killock
  • PARP inhibitors synergize with abiraterone June 20, 2018
    PARP inhibitors synergize with abirateronePARP inhibitors synergize with abiraterone, Published online: 21 June 2018; doi:10.1038/s41571-018-0060-9PARP inhibitors synergize with abiraterone
    Peter Sidaway
  • Ribociclib effective in HR<sup>+</sup>, HER2<sup>–</sup> breast cancer June 20, 2018
    Ribociclib effective in HR+, HER2– breast cancerRibociclib effective in HR+, HER2– breast cancer, Published online: 21 June 2018; doi:10.1038/s41571-018-0059-2Ribociclib effective in HR+, HER2– breast cancer
    Peter Sidaway
  • Ivosidenib effective in <i>IDH1</i>-mutant AML June 19, 2018
    Ivosidenib effective in IDH1-mutant AMLIvosidenib effective in IDH1-mutant AML, Published online: 20 June 2018; doi:10.1038/s41571-018-0057-4Ivosidenib effective in IDH1-mutant AML
    Peter Sidaway
  • Avoiding overuse of adjuvant therapies June 18, 2018
    Avoiding overuse of adjuvant therapiesAvoiding overuse of adjuvant therapies, Published online: 19 June 2018; doi:10.1038/s41571-018-0054-7Avoiding overuse of adjuvant therapies
    Diana Romero
  • Cemiplimab effective in cutaneous SCC June 18, 2018
    Cemiplimab effective in cutaneous SCCCemiplimab effective in cutaneous SCC, Published online: 19 June 2018; doi:10.1038/s41571-018-0056-5Cemiplimab effective in cutaneous SCC
    Peter Sidaway
  • To all involved — we have a problem June 6, 2018
    To all involved — we have a problemTo all involved — we have a problem, Published online: 07 June 2018; doi:10.1038/s41571-018-0052-9To all involved — we have a problem
    Diana Romero

  • Quizartinib tested in patients with high-risk AML June 21, 2018
    Quizartinib tested in patients with high-risk AMLQuizartinib tested in patients with high-risk AML, Published online: 22 June 2018; doi:10.1038/s41571-018-0061-8Quizartinib tested in patients with high-risk AML
    Peter Sidaway
  • Rituximab and ibrutinib synergize in Waldenström macroglobulinaemia June 20, 2018
    Rituximab and ibrutinib synergize in Waldenström macroglobulinaemiaRituximab and ibrutinib synergize in Waldenström macroglobulinaemia, Published online: 21 June 2018; doi:10.1038/s41571-018-0053-8Rituximab and ibrutinib synergize in Waldenström macroglobulinaemia
    David Killock
  • PARP inhibitors synergize with abiraterone June 20, 2018
    PARP inhibitors synergize with abirateronePARP inhibitors synergize with abiraterone, Published online: 21 June 2018; doi:10.1038/s41571-018-0060-9PARP inhibitors synergize with abiraterone
    Peter Sidaway
  • Ribociclib effective in HR<sup>+</sup>, HER2<sup>–</sup> breast cancer June 20, 2018
    Ribociclib effective in HR+, HER2– breast cancerRibociclib effective in HR+, HER2– breast cancer, Published online: 21 June 2018; doi:10.1038/s41571-018-0059-2Ribociclib effective in HR+, HER2– breast cancer
    Peter Sidaway
  • Ivosidenib effective in <i>IDH1</i>-mutant AML June 19, 2018
    Ivosidenib effective in IDH1-mutant AMLIvosidenib effective in IDH1-mutant AML, Published online: 20 June 2018; doi:10.1038/s41571-018-0057-4Ivosidenib effective in IDH1-mutant AML
    Peter Sidaway
  • Avoiding overuse of adjuvant therapies June 18, 2018
    Avoiding overuse of adjuvant therapiesAvoiding overuse of adjuvant therapies, Published online: 19 June 2018; doi:10.1038/s41571-018-0054-7Avoiding overuse of adjuvant therapies
    Diana Romero
  • Cemiplimab effective in cutaneous SCC June 18, 2018
    Cemiplimab effective in cutaneous SCCCemiplimab effective in cutaneous SCC, Published online: 19 June 2018; doi:10.1038/s41571-018-0056-5Cemiplimab effective in cutaneous SCC
    Peter Sidaway
  • To all involved — we have a problem June 6, 2018
    To all involved — we have a problemTo all involved — we have a problem, Published online: 07 June 2018; doi:10.1038/s41571-018-0052-9To all involved — we have a problem
    Diana Romero

Share

Leave a Reply

Your email address will not be published. Required fields are marked *


*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>